HC Wainwright set a $6.00 price target on Presbia (NASDAQ:LENS) in a research note issued to investors on Tuesday. The firm currently has a buy rating on the medical instruments supplier’s stock.
Separately, ValuEngine upgraded shares of Presbia from a sell rating to a hold rating in a research note on Wednesday, May 2nd.
LENS stock opened at $2.27 on Tuesday. Presbia has a 52 week low of $1.86 and a 52 week high of $7.14.
Presbia Company Profile
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany.
Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.